Once-a-day transplant drug may simplify life for kidney and liver patients
NCT ID NCT02882828
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at 134 kidney or liver transplant patients who switched from taking tacrolimus twice a day (Prograf) to once a day (Envarsus). Researchers measured drug levels in the blood before and after the switch to see if the once-daily version provides similar exposure. The goal is to make dosing easier and more convenient for patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tacrolimus (Prograf and Envarsus)
What this could lead to
If successful, this could show that switching to once-daily Envarsus maintains stable drug levels, making it easier for transplant patients to manage their medication.
What could go wrong
This is a small, completed Phase 4 study focused on drug levels, not long-term outcomes. Results may not apply to all transplant patients or guarantee better health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLOGRAFT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AP-HP
Paris, France
-
Limoges Hospital
Limoges, 87 042, France
-
University Hospital of Amiens
Amiens, France
-
University Hospital of Bordeaux
Bordeaux, France
-
University Hospital of Lille
Lille, France
-
University Hospital of Poitiers
Poitiers, France
-
University Hospital of Reims
Reims, France
-
University Hospital of Rouen
Rouen, France
-
University Hospital of Tours
Tours, France